March 8, 2017 09:18 AM EST
R&D

In­tel­lia fine tunes its CRISPR/Cas9 tech ahead of hu­man stud­ies

John Carroll

Editor & Founder

One of the hand­ful of gene ther­a­py star­tups has been fine tun­ing its CRISPR/Cas9 tech in the lead up to tak­ing it in­to hu­mans. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times